Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

Old people with neurodegenerative diseases
By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Secure, Real-World Data Drives Enhanced Insights for Neurodegenerative Disease Trials

Neurodegenerative diseases
By Dr. Natalia Drosopoulou, Executive Director of Project Management and Franchise Area Lead in Neuroscience, Worldwide Clinical Trials,

Neurodegenerative disease clinical trials are challenging, but they don’t have to be. Optimizing clinical trial patient recruitment and outcomes with external data sets can open new opportunities for pharma and biotech companies seeking to enhance their clinical trials in areas such as compliance, adherence, enrollment, safety, and even efficacy.

Read More

Insights into Brain Health and Central Nervous System (CNS) Clinical Trials

Brain Health, Michael Murphy
By the Editors of Talking Trials,

Brain health is one of 19 primary session topics that will be discussed at the Biotechnology Innovation Organization’s (BIO) annual conference. Neurological diseases are the leading cause of disability, according to a systematic analysis of data from 195 countries performed for the Global Burden of Disease Study 2015 (1). With 250.7 million years of healthy life lost due to death or disability caused by neurological disorders, this area of clinical research remains one of today’s most urgent challenges.

Read More

A Methodology for Advancing the Selection of Biomarkers for Use in Psychiatric Clinical Trials – Part 1

biomarkers in brain diagnostics
By Natalia Drosopoulou, Ph.D., Executive Director of Global Project Management, Neuroscience, Worldwide Clinical Trials,

  For this two-part blog series, Talking Trials asked Worldwide’s Dr. Drosopoulou, author of the recent article, “A Methodology for Advancing the Selection of Biomarkers for Use in Psychiatric Clinical Trials,” published in the Journal for Clinical Studies, to weigh in on the use of biomarkers for clinical research. Clinical trials using biomarkers in patient selection have higher overall success probabilities than clinical trials without biomarkers.1 That’s one of the many compelling results from a recent study of drug development success published in the journal Biostatistics. Wong and colleagues found clinical trials using biomarkers to stratify patients exhibit almost twice the overall probability of success compared to trials without biomarkers (10.3% vs. 5.5%).

Read More

Parkinson’s Disease Clinical Research: The Role of Vagotomy in Prevention of PD

By Tomislav Babic MD, PhD,

Early involvement of the gastrointestinal tract in development of Parkinson’s disease (PD) has been indicated by the presence of constipation in the premotor (prodromal) stage of PD. In fact, this is one of the earliest non-motor signs of PD, associated with occurrence of a-synuclein aggregation in gastrointestinal nerve endings forming Levy bodies in the gut several years before classical motor clinical presentation of Parkinson’s disease. Several recent studies of the gastrointestinal tract shed new light the prevention of PD and open avenues for larger neuroscience Parkinson’s disease research projects.

Read More